Tracey Rowlands

Regeneron (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index1.9kcitations17works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Wnt/β-catenin signaling in development and cancer(7), Cancer-related gene regulation(5), Cancer Immunotherapy and Biomarkers(4), Lung Cancer Treatments and Mutations(3), Bacterial Genetics and Biotechnology(2)

Publications17 total

A Phase I/II, multicenter, open-label study of REGN5668 (R5668; mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab or REGN4018 (R4018; MUC16 x CD3 bsAb) in patients with recurrent ovarian cancer (1309)
Gynecologic Oncology·2023Open Access
A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2020· 8 cited
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.
Journal of Clinical Oncology·2019· 5 cited
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 <sup>+</sup> T cell dysfunction and maintain memory phenotype
Science Immunology·2018· 161 cited
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Annals of Oncology·2018· 3 citedOpen Access
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.
Journal of Clinical Oncology·2018· 5 cited
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Pharmacology & Therapeutics·2014· 199 cited
Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment
Reviews in Endocrine and Metabolic Disorders·2011· 69 citedOpen Access
Cadherin Antagonists as Vasculature‐targeting Agents
2006· 2 cited
Cadherins and catenins in breast cancer
Current Opinion in Cell Biology·2005· 356 cited
b-Catenin and Cyclin D1: Connecting Development to Breast Cancer
Cell Cycle·2004· 41 citedOpen Access
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells
Proceedings of the National Academy of Sciences·2003· 514 citedOpen Access
Dissecting the roles of β-catenin and cyclin D1 during mammary development and neoplasia
Proceedings of the National Academy of Sciences·2003· 44 citedOpen Access
β-Catenin and Tcfs in Mammary Development and Cancer
Journal of Mammary Gland Biology and Neoplasia·2003· 207 cited
Plasma membrane components of adherens junctions (Review)
Molecular Membrane Biology·2002· 50 cited
Cloning and functional analysis of the TATA binding protein from Sulfolobus shibatae
Nucleic Acids Research·1995· 51 citedOpen Access
The TATA-Binding Protein: a General Transcription Factor in Eukaryotes and Archaebacteria
Science·1994· 189 cited

Frequent Co-authors

Pamela Cowin(5), Sarah Hatsell(4), Petra Rietschel(4), Israel Lowy(3), Víctor Moreno(3), Marta Gil-Martín(3), Raid Aljumaily(3), Lee S. Rosen(3), Kosalai Kal Mohan(3), Elizabeth Stankevich(3), Matthew G. Fury(3), Peter Baumann(2), Stephen P. Jackson(2), Orest W. Blaschuk(2), Irina V. Pechenkina(2), Emiliano Calvo(2), M.E. Olmedo García(2), Kyriakos P. Papadopoulos(2), Jingjin Li(2), Minjie Feng(2)